Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Do not exceed 12mg per week
Novo Nordisks Wegovy (semaglutide), the first and only once-weekly GLP-1 receptor agonist approved for weight management in people with obesity, has been found to help patients lose up to 15 percent of their body weight in over 68 weeks
By Lana Pine | Published on June 19, 2025 4 min read People with diabetes who take glucagon-like peptide-1 (GLP-1) receptor agonists (such as Ozempic and Wegovy) may have more than twice the risk of developing a serious eye condition called neovascular age-related macular degeneration (nAMD) a leading cause of vision loss in older adults according to a large-scale study published in JAMA Ophthalmology
Begin Your Advanced GLP-1 Journey At Advanced Aesthetics in Ocala, every step of your GLP-1 journey is designed with your wellness in mind
Please click here for Prescribing Information and Medication Guide for Wegovy
Ready to see if theres a study for you
